The Office Visit - 26/11/13

Résumé |
This article summarizes the current office-based evaluation of male infertility and offers speculation, based on current research, on the future evolution of this encounter. A comprehensive history, physical examination, and semen analysis remain paramount to directing the evaluation; however, new advances continue to refine diagnostic and treatment algorithms. Interpretation of the routine semen analysis as well as adjunctive assessments, including reactive oxygen species, DNA fragmentation, and fluorescent in situ hybridization (FISH) are discussed. The analysis of genetic and endocrine abnormalities is reviewed.
Le texte complet de cet article est disponible en PDF.Keywords : Male infertility, Semen analysis, Assisted reproductive technology, Men’s health
Plan
| Disclosures: R.P. Smith and R.M. Coward: None. L.I. Lipshultz: Repros Therapeutics, consultant; Eli Lilly Pharmaceuticals, speaker, scientific trial; Endo Pharmaceuticals, speaker, scientific trial; Auxilium Pharmaceuticals, speaker, scientific trial; Pfizer Pharmaceuticals, speaker; Allergan, scientific trial; American Medical Systems, speaker. |
|
| Sources of Funding: None. |
Vol 41 - N° 1
P. 19-37 - février 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
